Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea–hypnoea index (AHI).
- Resource Type
- Article
- Source
- BMJ Open; Jul2020, Vol. 10 Issue 7, p1-11, 11p
- Subject
- Language
- ISSN
- 20446055